

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014

Granada 25 February 2015

Relevant Fact of NEURON BIO

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB the company, Neuron Bio, S.A. (hereinafter "NEURON BIO" or the "Company"), hereby puts in knowledge the following information.

The US Patent and Trademark Office (USPTO) has issued the patent "*Use of statins as anticonvulsants, antiepileptics and neuroprotectors*" to NEURON BIO published with number US 8927599B2.

The patent protects the use of simvastatin in the treatment and prevention of epilepsy and its related seizures. Simvastatin is a known drug, commonly used for treating hypercholesterolaemia, something that might allow carrying out directly clinical assays in phase II (clinical proof of concept in humans) for the new patented indication.

This is the first patent granted to NEURON BIO by the US Patent and Trademark Office and could enable the Company to achieve commercial agreements with third parties on the use of simvastatine as an antiepileptic drug in United States.

In Granada 25 February 2015

Fernando Valdivieso Amate
Chairman of the Board of Directors